Karl Deisseroth, Peter Hegemann, and Georg Nagel were awarded the 2026 Nobel Prize in Physiology or Medicine for their pioneering discoveries that led to optogenetics, a method that uses light-sensitive proteins to switch individual nerve cells on or off in living brains. The announcement was made on 5 October 2026 and highlights significant advances with implications for neurological and psychiatric disorders.
Optogenetics harnesses light-controlled proteins originally found in algae to activate specific neurons with remarkable precision. “What we figured out was how to use light to control cells in the brain,” said Deisseroth in an interview following the announcement. The Nobel Committee Chair, Per Svenningsson, described it as providing “opportunities for mapping the brain in a way that we could once only dream of.”
Since Deisseroth’s first demonstration in 2005 that channelrhodopsin could function as a light switch for nerve cells, the method was named optogenetics in 2006. By 2007, Deisseroth successfully activated neurons in live mice, and in 2012, the team identified cells critical for memory formation.
The Nobel committee highlighted the broader implications for treatments in blindness, depression, addiction, dementia, and other brain disorders. Cases of partial vision restoration using optogenetics have already been reported in clinical studies with patients suffering from retinitis pigmentosa, a degenerative eye disease destroying the retina’s rods and cones. One blind patient regained some vision, able to discern and grasp objects on a table wearing special glasses emitting light linked to the introduced protein.
“The impact of optogenetics extends far beyond understanding the healthy brain,” Nobel committee member and neuroscientist Abdel El Manira said, emphasizing its role in uncovering brain circuit disruptions linked to serious conditions. However, while optogenetics holds promise for dementia and Alzheimer’s research, confirmed, effective treatments for Alzheimer’s using this technology remain unproven at this stage.
Optogenetics is being used in ongoing trials focused on restoring sight for retinal diseases, positioning it at the forefront of experimental therapies. The work’s clinical translation from algae proteins to potential treatments marks a significant advance in brain science and medicine.
Despite the promising progress, official sources note that optogenetics’ application in Alzheimer’s disease therapy is still exploratory without current established treatments. The Cape Flats News will continue monitoring developments in this field and report on new clinical trial outcomes and treatment breakthroughs as they occur.